ILD/DPLD of known origin最新文献

Prevalence and associated risk factors of post covid-19 interstitial lung disease; An emerging challenge to pulmonologists 2019冠状病毒病后间质性肺病患病率及相关危险因素肺科医生面临的新挑战

ILD/DPLD of known origin Pub Date : 2022-03-10 DOI: 10.1183/23120541.lsc-2022.170

D. Yasaratne, A. Shantha, Safa Shafee, Nuwani Nissanka, A. Thilakarathne, A. Medagama

引用次数: 0

Interstitial pneumonia with autoimmune features associated with myositis autoantibodies: clinical characteristics from a multicenter Latin-American cohort 与肌炎自身抗体相关的自身免疫特征的间质性肺炎:来自多中心拉丁美洲队列的临床特征

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa1371

José Ernesto Juárez León, M. L. Alberti, V. Wolff, F. Reyes, F. Paulin, L. Fassola, F. Caro, G. Carballo, Tamara Palavecino, Juan Carlos Rodríguez Díaz, I. Roldán, M. Mejía, M. Florenzano, J. Serrano

引用次数: 0

Pneumotox metrics: Drugs, patterns, users and countries. Foreground and quiet zones 肺毒素指标:药物、模式、使用者和国家。前景和宁静区

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.oa1613

P. Camus, C. Camus, G. Beltramo, P. Bonniaud

引用次数: 0

Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial 尼达尼布对系统性硬化症相关ILD (SSc-ILD)和不同FVC基线患者的影响:SENSCIS试验

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.oa3599

Toby M. Maher, O. Distler, A. Azuma, Aryeh Fischer, Kristin B. Highland, Masataka Kuwana, Maureen D. Mayes, D. Wachtlin, M. Alves, M. Gahlemann, S. Stowasser, G. Raghu

引用次数: 0

IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease IGFBP-2:系统性硬化症相关间质性肺疾病的新途径

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.oa3597

F. Gester, M. Henket, Dominique Deseny, C. Moermans, B. André, M. Malaise, R. Louis, J. Guiot

{"title":"IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease","authors":"F. Gester, M. Henket, Dominique Deseny, C. Moermans, B. André, M. Malaise, R. Louis, J. Guiot","doi":"10.1183/13993003.congress-2019.oa3597","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.oa3597","url":null,"abstract":"Background: Systemic sclerosis (SSc) is a rare connective tissue disease associated with potential rapid evolving interstitial lung disease (SSc-ILD), driving the mortality of these patients. Therefore, a specific biomarker associated with the evolution of that disease is highly needed to identify patients with an increased risk of death. Aim of the Study: Identify specific biomarkers of SSc-ILD to predict the evolution of the disease. Methods: In this prospective longitudinal study, we compared serum levels of biomarkers assumed to be associated with lung fibrosis (TGF-β, IGF-1, IGFBP-1, IGFBP-2, IGFBP-3, IL-8, MMP-7, MMP-9, YKL-40 and TNF-α) among three groups: SSc-ILD (n=39), SSc without ILD (n=63) and healthy subjects (HS)(n=39). We also prospectively analyzed variations of biomarkers and correlated them to pulmonary function tests (n=28). Then, we realized an in vitro analysis to study the potential anti-fibrotic effect of IGFBP-2 (n=3). Results: IGFBP-2, IL-8 and MMP-9 are increased in SSc patients compared to HS (p Conclusion: IGFBP-1 has a potential interest to identify early SSc-ILD whereas IGFBP-2 would rather predict the risk of a rapid evolution of lung fibrosis. Moreover, in vitro studies confirmed the anti-fibrotic effect of IGFBP-2 underlying its potential interest in further mechanical studies and therapeutic aspects.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"87 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122951019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

A single center experience of rituximab for anti synthetase syndrome associated interstitial lung disease (ASS-ILD) 单中心利妥昔单抗治疗抗合成酶综合征相关间质性肺疾病(ASS-ILD)

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa1367

A. Rathnapala, L. Wing, R. Benamore, J. David, R. Hoyles

引用次数: 0

Features and functional deterioration in interstitial lung disease (ILD) asociated to rheumatoid arthritis (RA) 类风湿关节炎(RA)相关间质性肺疾病(ILD)的特征和功能恶化

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa4742

M. A. N. Barbero, C. Vadillo, F. Pelaez, Ana Palomar, L. Abasolo

{"title":"Features and functional deterioration in interstitial lung disease (ILD) asociated to rheumatoid arthritis (RA)","authors":"M. A. N. Barbero, C. Vadillo, F. Pelaez, Ana Palomar, L. Abasolo","doi":"10.1183/13993003.congress-2019.pa4742","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa4742","url":null,"abstract":"Purpose: To describe the characteristics of ILD-RA patients and to asess their inicence rate of functional respiratory impairment Methods: This is a longitudinal prospective study. A cohort of RA patients diagnosed of ILD since 02/2007 until 03/2018 and followed till 05/2018, in a ILD unit, carried by a pneumologist and a rheumatologist. The main variable was FVC decline ≥ 10 % pred value since the previous visit. Covariables: sociodemographic, basal comorbidities, radiological pattern (UIP, NSIP), laboratory tests, therapy (corticoids, Azathioprine [AZA], Mycophenolate [MMF], Leflunomide [LEF], anti-TNF, Abatacept [ABA], Rituximab [RTX]. Survival techniques were used to estimate the incidence rate (IR) of functional impairment, expressed per 100 patient-years [95 % CI]. Results: We included 43 patients, 63% women, mean age 70±9.6 years. 42% never smoked. HTN and vascular disease were frecuent comorbidities, RF was positive in 85% and anti-CCP in 82%, ESR was 43±26. UIP pattern in 63%, NSIP in 32 %. Median FVC were 103%. 33 patients used Corticoids, 4 MMF, 18 AZA, 16 LEF, 6 TNFs, 20 RTX and 5 ABA. 37% sufered functional deterioration, IR of 17 [11-25] (141 patients-years). 50% achieved funtional deterioration at 4.6 years since the ILD diagnosis. IR for UIP was 18 [11-30] and for NSIP 16 [8-29]. Corticoids IR was 15[10-24], LEF 13[6-29], AZA and MMF 17[8-36], RTX 11 [4-29] Conclusion: RA patients had active disease at ILD diagnosis. The most common radiological pattern was UIP. 37% of patients suffered functional deterioration with IR of 17% patient-years, being 4.5 years the median time free of impairment. The crude incidence of functional impairment was less for RTX.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"116 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126706594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interstitial lung disease associated with ANCA positivity: a retrospective analysis 与ANCA阳性相关的间质性肺疾病:回顾性分析

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa1362

S. Juman, S. Haque, N. Chaudhuri

引用次数: 1

Death in ILD - Why arent we talking about it? ILD中的死亡-为什么我们不谈论它?

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa5186

A. Hudson, A. Hare, L. Berry, Linda Freeman, P. George

{"title":"Death in ILD - Why arent we talking about it?","authors":"A. Hudson, A. Hare, L. Berry, Linda Freeman, P. George","doi":"10.1183/13993003.congress-2019.pa5186","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa5186","url":null,"abstract":"Background: There is growing appreciation for early palliative care (PC) input in the management of patients with interstitial lung disease (ILD). Patients receiving PC experience improved quality of life, but it is our anecdotal experience that PC input may not always be introduced promptly. Aim: The aim was to increase the regularity with which the ILD MDT discussed end of life (EOL) care and to improve the quality of patient care. Methods: 21 ILD Clinicians working in a tertiary unit were surveyed and ILD inpatients were interviewed. The results of the initial survey led to three interventions:(a)Regular attendance of the PC team at inpatient ward reviews,(b) Routine implementation of the surprise question; “Would you be surprised if this patient died within the next 12 months” and (c)Written documentation identifying patients appropriate for PC. Results: 81% of clinicians surveyed felt that EOL conversations with patients could be timelier. Reasons cited for delayed discussion included ambiguity of patient wishes, unpredictability of disease behaviour and uncertainty of prognosis. Prior to the interventions, only 40% of ILD inpatients had PC discussed; within 14 weeks this increased to 100%. There was an average increase of 3.21 minutes per patient in discussion time. The number of referrals to PC increased, as did patient awareness of advanced care planning. The intervention also prompted 2 new transplant referrals. Patient experience interviews were conducted and responses were universally positive. Conclusion: Implementation of PC conversations in this group can be challenging due to the difficulty in predicting trajectory of disease. Routine involvement of the PC team is valued by inpatients with ILD and may improve outcomes.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"92 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126161052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cellular consequences of uncharacterized surfactant protein-A2 (SFTPA2)-gene mutations associated with familial IPF and lung cancer 与家族性IPF和肺癌相关的未表征表面活性蛋白a2 (SFTPA2)基因突变的细胞后果

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.oa1608

K. Guenther, W. Seeger, A. Guenther, M. Korfei

引用次数: 2